riflewine95
About
Basic safety and also immunogenicity associated with an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in 2 products: a couple of open, non-randomised stage 1/2 reports via Russian federation.
Basic safety and also immunogenicity associated with an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in 2 products: a couple of open, non-randomised stage 1/2 reports via Russian federation.